The Patent Finder
MR

Monte Rosa Therapeutics AG

First filing 2022
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Four patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2042. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2042
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2024 to 2044.
US 11,912,682 Isoindolinone Compounds Jan 13, 2042
US 12,391,663 Isoindolinone Compounds Jan 13, 2042
US 12,257,247 Targeted Degradation of VAV1 Jan 8, 2044
US 12,459,920 Targeted Protein Degradation Jul 24, 2044
20282032203620402044
28 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Isoindolinone Compounds (US 11,912,682) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Isoindolinone Compounds2 in forceto Jan 2042
Targeted Protein Degradation1 in forceto Jul 2044
Targeted Degradation of VAV11 in forceto Jan 2044

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

PatentTitleStatusExpiresConfidence
US 11,912,682Isoindolinone Compounds
In force
 · High confidence
In forceHigh confidence
US 12,391,663Isoindolinone Compounds
In force
 · High confidence
In forceHigh confidence
US 12,257,247Targeted Degradation of VAV1
In force
 · High confidence
In forceHigh confidence
US 12,459,920Targeted Protein Degradation
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 28 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited